These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17697055)

  • 1. The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.
    Mathur G; Noronha B; Rodrigues E; Davis G
    Diabetes Obes Metab; 2007 Sep; 9(5):617-29. PubMed ID: 17697055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
    Kintscher U; Unger T
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Renin-Angiotensin system and vascular disease in diabetes.
    Deinum J; Chaturvedi N
    Semin Vasc Med; 2002 May; 2(2):149-56. PubMed ID: 16222606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
    Braga MF; Leiter LA
    Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
    Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
    Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel].
    Berar-Yanay N; Leshno M; Hertzeanu L; Weintrob N
    Harefuah; 2008 Mar; 147(3):211-5, 278. PubMed ID: 18488861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
    Armario P; de la Sierra A
    Ther Adv Cardiovasc Dis; 2009 Jun; 3(3):197-204. PubMed ID: 19443514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.